1887

Abstract

Two important issues regarding a virus mutant that is resistant to an antiviral drug are its ability to replicate in animal hosts ( fitness) relative to other genetic variants, including wild type, and its ability to cause disease. These issues have been investigated for a herpes simplex virus 1 mutant that is resistant to thiourea compounds, which inhibit encapsidation of viral DNA. Following corneal inoculation of mice, the mutant virus replicated very similarly to its wild-type parent in the eye, trigeminal ganglion and brain. The mutant virus was as lethal to mice as its wild-type parent following this route of inoculation. Indeed, it exhibited increased virulence. Thus, unlike most drug-resistant virus mutants, this mutant retained fitness and virulence.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82787-0
2007-05-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/5/1410.html?itemId=/content/journal/jgv/10.1099/vir.0.82787-0&mimeType=html&fmt=ahah

References

  1. Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T. & Sutton, D. ( 2003; ). Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 16, 114–128.[CrossRef]
    [Google Scholar]
  2. Bean, W. J., Threlkeld, S. C. & Webster, R. G. ( 1989; ). Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 159, 1050–1056.[CrossRef]
    [Google Scholar]
  3. Chen, S. H., Cook, W. J., Grove, K. L. & Coen, D. M. ( 1998; ). Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant. J Virol 72, 6710–6715.
    [Google Scholar]
  4. Coen, D. M. ( 1994; ). Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 2, 481–485.[CrossRef]
    [Google Scholar]
  5. Coen, D. M. & Richman, D. D. ( 2007; ). Antiviral agents. In Fields Virology, 5th edn, pp. 447–485. Edited by D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman & S. E. Straus. Philadelphia, PA: Lippincott Williams & Wilkins.
  6. Coen, D. M. & Schaffer, P. A. ( 2003; ). Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat Rev Drug Discov 2, 278–288.[CrossRef]
    [Google Scholar]
  7. Coen, D. M., Irmiere, A. F., Jacobson, J. G. & Kerns, K. M. ( 1989; ). Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168, 221–231.[CrossRef]
    [Google Scholar]
  8. Desai, P., DeLuca, N. A. & Person, S. ( 1998; ). Herpes simplex virus type 1 VP26 is not essential for replication in cell culture but influences production of infectious virus in the nervous system of infected mice. Virology 247, 115–124.[CrossRef]
    [Google Scholar]
  9. Enquist, L. W., Husak, P. J., Banfield, B. W. & Smith, G. A. ( 1998; ). Infection and spread of alphaherpesviruses in the nervous system. Adv Virus Res 51, 237–347.
    [Google Scholar]
  10. Field, H. J. & Coen, D. M. ( 1986; ). Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol 60, 286–289.
    [Google Scholar]
  11. Jacobson, J., Kramer, M., Rozenberg, F., Hu, A. & Coen, D. M. ( 1995; ). Synergistic effects on ganglionic herpes simplex virus infections by mutations or drugs that inhibit the viral polymerase and thymidine kinase. Virology 206, 263–268.[CrossRef]
    [Google Scholar]
  12. Larder, B. A. & Darby, G. ( 1984; ). Virus drug-resistance: mechanisms and consequences. Antiviral Res 4, 1–42.[CrossRef]
    [Google Scholar]
  13. Leib, D. A., Coen, D. M., Bogard, C. L., Hicks, K. A., Yager, D. R., Knipe, D. M., Tyler, K. L. & Schaffer, P. A. ( 1989; ). Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol 63, 759–768.
    [Google Scholar]
  14. Newcomb, W. W. & Brown, J. C. ( 2002; ). Inhibition of herpes simplex virus replication by WAY-150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. J Virol 76, 10084–10088.[CrossRef]
    [Google Scholar]
  15. Newcomb, W. W., Juhas, R. M., Thomsen, D. R., Homa, F. L., Burch, A. D., Weller, S. K. & Brown, J. C. ( 2001; ). The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J Virol 75, 10923–10932.[CrossRef]
    [Google Scholar]
  16. Newcomb, W. W., Thomsen, D. R., Homa, F. L. & Brown, J. C. ( 2003; ). Assembly of the herpes simplex virus capsid: identification of soluble scaffold-portal complexes and their role in formation of portal-containing capsids. J Virol 77, 9862–9871.[CrossRef]
    [Google Scholar]
  17. Oxford, J. S. & Potter, C. W. ( 1973; ). Aminoadamantane-resistant strains of influenza A2 virus. J Hyg (Lond) 71, 227–236.[CrossRef]
    [Google Scholar]
  18. Patel, A. H., Rixon, F. J., Cunningham, C. & Davison, A. J. ( 1996; ). Isolation and characterization of herpes simplex virus type 1 mutants defective in the UL6 gene. Virology 217, 111–123.[CrossRef]
    [Google Scholar]
  19. Pelosi, E., Mulamba, G. B. & Coen, D. M. ( 1998a; ). Penciclovir and pathogenesis phenotypes of drug-resistant herpes simplex virus mutants. Antiviral Res 37, 17–28.[CrossRef]
    [Google Scholar]
  20. Pelosi, E., Rozenberg, F., Coen, D. M. & Tyler, K. L. ( 1998b; ). A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice. Virology 252, 364–372.[CrossRef]
    [Google Scholar]
  21. Pesola, J. M., Zhu, J., Knipe, D. M. & Coen, D. M. ( 2005; ). Herpes simplex virus 1 immediate-early and early gene expression during reactivation from latency under conditions that prevent infectious virus production. J Virol 79, 14516–14525.[CrossRef]
    [Google Scholar]
  22. Safrin, S., Elbeik, T., Phan, L., Robinson, D., Rush, J., Elbaggari, A. & Mills, J. ( 1994; ). Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 38, 1246–1250.[CrossRef]
    [Google Scholar]
  23. Sherman, G. & Bachenheimer, S. L. ( 1988; ). Characterization of intranuclear capsids made by ts morphogenic mutants of HSV-1. Virology 163, 471–480.[CrossRef]
    [Google Scholar]
  24. Stevens, J. G. & Cook, M. L. ( 1971; ). Latent herpes simplex virus in spinal ganglia of mice. Science 173, 843–845.[CrossRef]
    [Google Scholar]
  25. Sweet, C., Hayden, F. G., Jakeman, K. J., Grambas, S. & Hay, A. J. ( 1991; ). Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 164, 969–972.[CrossRef]
    [Google Scholar]
  26. Tenser, R. B. & Dunstan, M. E. ( 1979; ). Herpes simplex virus thymidine kinase expression in infection of the trigeminal ganglion. Virology 99, 417–422.[CrossRef]
    [Google Scholar]
  27. Tran, R. K., Lieu, P. T., Aguilar, S., Wagner, E. K. & Bloom, D. C. ( 2002; ). Altering the expression kinetics of VP5 results in altered virulence and pathogenesis of herpes simplex virus type 1 in mice. J Virol 76, 2199–2205.[CrossRef]
    [Google Scholar]
  28. Trus, B. L., Cheng, N., Newcomb, W. W., Homa, F. L., Brown, J. C. & Steven, A. C. ( 2004; ). Structure and polymorphism of the UL6 portal protein of herpes simplex virus type 1. J Virol 78, 12668–12671.[CrossRef]
    [Google Scholar]
  29. van Zeijl, M., Fairhurst, J., Jones, T. R., Vernon, S. K., Morin, J., LaRocque, J., Feld, B., O'Hara, B., Bloom, J. D. & Johann, S. V. ( 2000; ). Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. J Virol 74, 9054–9061.[CrossRef]
    [Google Scholar]
  30. Visalli, R. J. & van Zeijl, M. ( 2003; ). DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Res 59, 73–87.[CrossRef]
    [Google Scholar]
  31. Zhao, Z. S., Granucci, F., Yeh, L., Schaffer, P. A. & Cantor, H. ( 1998; ). Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 279, 1344–1347.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82787-0
Loading
/content/journal/jgv/10.1099/vir.0.82787-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error